Myasthenia Gravis Market Is Anticipated to Be Worth US$2,313.1 Mn by the End of 2025
Despite a largely consolidated vendor landscape with several large players and a few regional players, competition in the global Myasthenia Gravis Market is stiff. In this scenario, key players hold small market shares. Alexion Pharmaceutical Inc., Avadel Pharmaceuticals plc, CSL Behring, Grifols S.A., Baxter International Inc., Shire plc, Novartis AG, F. Hoffmann-La Roche AG, Takeda Pharmaceutical Company Limited, and Valeant Pharmaceuticals International Inc. are to name some prominent companies in the global myasthenia gravis market. These companies are focused on...
View full press release